Analyses of predictive factors for refractory GVHD in all 104 patients
| Parameter . | Odds ratio (95% CI) . | P . |
|---|---|---|
| More than 50 y old | 1.21 (0.35-4.19) | .76 |
| High disease risk | 1.29 (0.44-3.76) | .65 |
| Graft PB (vs BM) | 1.19 (0.23-6.11) | .83 |
| Unrelated donor | 0.91 (0.30-2.73) | .86 |
| HLA mismatch | 1.96 (0.66-5.84) | .23 |
| Conventional regimens | 0.94 (0.27-3.23) | .92 |
| Skin stage 3 or 4 at biopsy | 1.97 (0.69-5.68) | .21 |
| MT (> 100 CD8+ cells) | 1.26 (0.37-4.27) | .71 |
| MM (> 200 CD163+ cells) | 3.79 (1.22-11.8) | .02 |
| Parameter . | Odds ratio (95% CI) . | P . |
|---|---|---|
| More than 50 y old | 1.21 (0.35-4.19) | .76 |
| High disease risk | 1.29 (0.44-3.76) | .65 |
| Graft PB (vs BM) | 1.19 (0.23-6.11) | .83 |
| Unrelated donor | 0.91 (0.30-2.73) | .86 |
| HLA mismatch | 1.96 (0.66-5.84) | .23 |
| Conventional regimens | 0.94 (0.27-3.23) | .92 |
| Skin stage 3 or 4 at biopsy | 1.97 (0.69-5.68) | .21 |
| MT (> 100 CD8+ cells) | 1.26 (0.37-4.27) | .71 |
| MM (> 200 CD163+ cells) | 3.79 (1.22-11.8) | .02 |